12:00 AM
 | 
Apr 05, 2004
 |  BioCentury  |  Strategy

Evotec: Putting risk into buckets

Evotec OAI AG has been taking careful steps to add discovery to its high throughput screening and medicinal chemistry service business, trying to manage the risk it takes by funding certain programs internally, some via joint ventures, and some via venture capital. The approach was exemplified last week by a E25 million ($30 million) series A venture round for its Evotec Neurosciences subsidiary, which is part of the company's discovery programs division (DPD).

DPD consists of three units: Evotec Neurosciences GmbH; an alliance that was formed last September with DeveloGen AG (Goettingen, Germany); and the Vmax Ltd. joint venture with infectious diseases play

Read the full 510 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >